Barclays PLC Has $7.03 Million Stock Position in Arcellx, Inc. (NASDAQ:ACLX)

Barclays PLC increased its holdings in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 7.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 91,595 shares of the company's stock after buying an additional 6,273 shares during the quarter. Barclays PLC owned 0.17% of Arcellx worth $7,025,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. FMR LLC grew its stake in Arcellx by 22.8% in the fourth quarter. FMR LLC now owns 7,956,633 shares of the company's stock valued at $610,194,000 after purchasing an additional 1,477,360 shares in the last quarter. Vanguard Group Inc. grew its stake in Arcellx by 35.3% in the fourth quarter. Vanguard Group Inc. now owns 3,330,092 shares of the company's stock valued at $255,385,000 after purchasing an additional 867,996 shares in the last quarter. Geode Capital Management LLC grew its stake in Arcellx by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 979,026 shares of the company's stock valued at $75,098,000 after purchasing an additional 4,059 shares in the last quarter. Lord Abbett & CO. LLC grew its stake in Arcellx by 2.1% in the third quarter. Lord Abbett & CO. LLC now owns 891,848 shares of the company's stock valued at $74,478,000 after purchasing an additional 18,004 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Arcellx by 4.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 343,085 shares of the company's stock valued at $26,311,000 after purchasing an additional 14,992 shares in the last quarter. Hedge funds and other institutional investors own 96.03% of the company's stock.

Insider Transactions at Arcellx

In related news, insider Christopher Heery sold 10,155 shares of the business's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $63.79, for a total transaction of $647,787.45. Following the completion of the transaction, the insider now owns 37,486 shares of the company's stock, valued at approximately $2,391,231.94. The trade was a 21.32 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rami Elghandour sold 38,300 shares of the company's stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $62.02, for a total value of $2,375,366.00. Following the completion of the transaction, the insider now directly owns 149,186 shares of the company's stock, valued at approximately $9,252,515.72. This trade represents a 20.43 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 55,955 shares of company stock worth $3,504,758. 6.24% of the stock is owned by corporate insiders.

Arcellx Trading Up 0.4 %

NASDAQ ACLX traded up $0.24 on Wednesday, reaching $64.95. The stock had a trading volume of 305,269 shares, compared to its average volume of 554,529. The company has a market capitalization of $3.58 billion, a price-to-earnings ratio of -91.48 and a beta of 0.33. The business has a 50 day moving average price of $64.77 and a 200 day moving average price of $74.43. Arcellx, Inc. has a 1 year low of $47.88 and a 1 year high of $107.37.

Arcellx (NASDAQ:ACLX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.24). The company had revenue of $15.27 million for the quarter, compared to the consensus estimate of $27.42 million. Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. On average, analysts anticipate that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).